FY2025 Earnings Estimate for ABUS Issued By Chardan Capital

Arbutus Biopharma Co. (NASDAQ:ABUS) – Chardan Capital boosted their FY2025 EPS estimates for shares of Arbutus Biopharma in a research report issued to clients and investors on Monday, March 24th. Chardan Capital analyst K. Nakae now anticipates that the biopharmaceutical company will post earnings per share of ($0.30) for the year, up from their previous estimate of ($0.38). The consensus estimate for Arbutus Biopharma’s current full-year earnings is ($0.39) per share.

Arbutus Biopharma (NASDAQ:ABUS) last announced its quarterly earnings results on Thursday, March 27th. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.01. The company had revenue of $1.57 million for the quarter, compared to the consensus estimate of $2.20 million. Arbutus Biopharma had a negative return on equity of 68.18% and a negative net margin of 1,137.65%.

ABUS has been the subject of a number of other research reports. HC Wainwright reaffirmed a “buy” rating and issued a $5.00 price target on shares of Arbutus Biopharma in a research note on Tuesday, January 21st. StockNews.com cut shares of Arbutus Biopharma from a “hold” rating to a “sell” rating in a research report on Thursday, March 13th. One analyst has rated the stock with a sell rating and four have issued a buy rating to the company. According to MarketBeat, Arbutus Biopharma currently has an average rating of “Moderate Buy” and an average price target of $5.50.

Arbutus Biopharma Stock Performance

Shares of ABUS stock opened at $3.27 on Thursday. Arbutus Biopharma has a fifty-two week low of $2.30 and a fifty-two week high of $4.73. The firm has a market cap of $619.64 million, a P/E ratio of -7.60 and a beta of 1.93. The business’s 50 day moving average price is $3.33 and its 200-day moving average price is $3.58.

Institutional Investors Weigh In On Arbutus Biopharma

Hedge funds have recently made changes to their positions in the company. Invesco Ltd. lifted its position in Arbutus Biopharma by 5.7% during the fourth quarter. Invesco Ltd. now owns 69,831 shares of the biopharmaceutical company’s stock valued at $228,000 after buying an additional 3,780 shares during the period. China Universal Asset Management Co. Ltd. increased its stake in shares of Arbutus Biopharma by 10.7% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 40,179 shares of the biopharmaceutical company’s stock worth $131,000 after acquiring an additional 3,870 shares in the last quarter. Clear Harbor Asset Management LLC lifted its position in Arbutus Biopharma by 6.7% during the 4th quarter. Clear Harbor Asset Management LLC now owns 79,761 shares of the biopharmaceutical company’s stock valued at $261,000 after acquiring an additional 5,000 shares during the period. Teacher Retirement System of Texas boosted its stake in Arbutus Biopharma by 18.7% during the fourth quarter. Teacher Retirement System of Texas now owns 42,144 shares of the biopharmaceutical company’s stock worth $138,000 after acquiring an additional 6,644 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Arbutus Biopharma by 10.2% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 89,397 shares of the biopharmaceutical company’s stock worth $292,000 after purchasing an additional 8,308 shares during the period. 43.79% of the stock is currently owned by institutional investors.

About Arbutus Biopharma

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression.